This article is more than 5 years old. Information may no longer be current.

Imprimis reports $4.6 million net loss in second quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Imprimis Pharmaceuticals reported a net loss of $4.6 million, or $0.35 per common share, in the second quarter compared with a net loss of $3.7 million, or $0.39 per common share, in the second quarter of 2015, according to a press release.

Total revenue in the second quarter was $4.9 million, a nearly 150% increase from approximately $2 million a year ago. Ophthalmology-related revenue totaled $2.6 million, an increase of more than 330%.

Research and development expenses totaled $76,000 compared with $25,000 in the second quarter of 2015, sales and marketing expenses totaled $2.3 million compared with $1.6 million, and general and administrative expenses totaled $4.4 million compared with $2.7 million.